In vitro inhibition of human influenza A virus replication by chloroquine

被引：109

作者：

Ooi, Eng Eong ^{[1
]}

Chew, Janet Seok Wei ^{[1
]}

Loh, Jin Phang ^{[1
]}

Chua, Robert C. S. ^{[1
]}

机构：

[1] DSO Natl Labs, Def Med & Environm Res Inst, Singapore 117510, Singapore

来源：

VIROLOGY JOURNAL | 2006年 / 3卷 / 1期

关键词：

D O I：

10.1186/1743-422X-3-39

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Chloroquine is a 9-aminoquinolone with well-known anti-malarial effects. It has biochemical properties that could be applied to inhibit viral replication. We report here that chloroquine is able to inhibit influenza A virus replication, in vitro, and the IC50s of chloroquine against influenza A viruses H1N1 and H3N2 are lower than the plasma concentrations reached during treatment of acute malaria. The potential of chloroquine to be added to the limited range of anti-influenza drugs should be explored further, particularly since antiviral drugs play a vital role in influenza pandemic preparedness.

引用

页数：3

共 13 条

[1]

Al-Jabri A. A., 1996, P293, DOI 10.1016/B978-012465330-6/50015-4

[2] The potential place of chloroquine in the treatment of HIV-1-infected patients [J].

Boelaert, JR ;

Piette, J ;

Sperber, K .

JOURNAL OF CLINICAL VIROLOGY, 2001, 20 (03) :137-140

[3] Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States [J].

Bright, RA ;

Shay, DK ;

Shu, B ;

Cox, NJ ;

Klimov, AI .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (08) :891-894

[4] Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? [J].

Cheung, CY ;

Poon, LLM ;

Lau, AS ;

Luk, W ;

Lau, YL ;

Shortridge, KF ;

Gordon, S ;

Guan, Y ;

Peiris, JSM .

LANCET, 2002, 360 (9348) :1831-1837

[5] Brief report - Oseltamivir resistance during treatment of influenza A (H5N1) infection [J].

de Jong, MD ;

Thanh, TT ;

Khanh, TH ;

Hien, VM ;

Smith, GJD ;

Chau, NV ;

Cam, BV ;

Qui, PT ;

Ha, DQ ;

Guan, Y ;

Peiris, JSM ;

Hien, TT ;

Farrar, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) :2667-2672

[6] Clinical pharmacokinetics and metabolism of chloroquine - Focus on recent advancements [J].

Ducharme, J ;

Farinotti, R .

CLINICAL PHARMACOKINETICS, 1996, 31 (04) :257-274

[7] Recovery of drug-resistant influenza virus from immunocompromised patients: A case series [J].

Ison, MG ;

Gubareva, LV ;

Atmar, RL ;

Treanor, J ;

Hayden, FG .

JOURNAL OF INFECTIOUS DISEASES, 2006, 193 (06) :760-764

[8] In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine [J].

Keyaerts, E ;

Vijgen, L ;

Maes, P ;

Neyts, J ;

Van Ranst, M .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 323 (01) :264-268

[9] Oseltamivir resistance - Disabling our influenza defenses [J].

Moscona, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) :2633-2636

[10]

Savirno A, 2003, LANCET INFECT DIS, V3, P772

← 1 2 →